This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

24/7 Access
Digital & In-Person

Don Parsons, PhD
VP, Early Technical Development and LNP Process Development at Moderna Therapeutics


Dr. Donald Parsons is Vice President, Early Technical Development and Lipid Nanoparticle Process Development at Moderna Therapeutics in Norwood, Massachusetts, USA. The research of his team focuses on the fundamental process science behind the manufacture of lipid nanoparticles for mRNA delivery; and the development and scaleup of these processes. Additionally, he plays a matrix leadership role coordinating CMC activities for Moderna’s early-phase clinical pipeline; as well as leading Moderna’s small molecule process chemistry efforts. Prior to his tenure at Moderna, Don spent six years with BIND Therapeutics in Cambridge, Massachusetts, where he led analytical development and process chemistry functions supporting the development and clinical translation of small molecule-loaded polymeric nanoparticles as Vice President, Pharmaceutical Development. Don has extensive experience in the clinical translation of complex drug delivery systems, including process development, analytical characterization, and application of Quality by Design principles to these systems.

Agenda Sessions

  • Rapid Deployment of a Messenger RNA Vaccine for Pandemic Response

    On Demand - Premium Only